Loading
Life sciences · Journal article
Indonesian Journal of Cardiology · October 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Current risk-prediction models for Cancer Therapy–Related Cardiovascular Toxicity (CTR-CVT) rely predominantly on demographic, diagnostic, and treatment variables, lacking genetic determinants of individual susceptibility. Recent evidence suggests cardiomyopathy-associated genetic variants, particularly Titin-truncating variants (TTNtv), may be significant in CTR-CVT development. This review examines the occurrence and impact of TTNtv in CTR-CVT patients. We conducted a PRISMA-guided review analyzing TTNtv in patients with chemotherapy exposure who developed cardiomyopathy. Literature searches were performed in PubMed and Scopus using keywords: “(cardiomyopathy OR heart failure) AND (chemotherapy OR cancer therapy) AND (Titin OR TTNtv).” Quality assessment employed the Newcastle-Ottawa Scale (NOS) for observational studies and the Joanna Briggs Institute (JBI) criteria for case reports. We included 2 case-control studies and 2 case reports. TTNtv prevalence was significantly higher in chemotherapy-induced cardiomyopathy than in controls: 7.5% versus 0.6-1.1% (multicenter cohort), and 6.5% versus 0% (single-center cohort). There are conflicting results regarding symptom severity and prognosis among those with and without TTNtv mutation. One multicenter case-control study with animal model validation demonstrated that chemotherapy is poorly tolerated in TTNtv carriers. Chemotherapy-to-symptom onset ranged from 0.4 to 9 years and primarily involved anthracyclines. Among truncating variations found in the included literature, localization in the A-band of the titin protein predominated. TTNtv represents a predominant genetic determinant in CTR-CVT susceptibility, although its association with severity and recovery outcomes remains inconsistent across studies. Genetic screening could identify high-risk cancer patients benefiting from personalized cardioprotective strategies and enable assessment of prophylactic interventions. Future investigations will determine if early genetic risk recognition optimizes cancer and cardiovascular treatments, potentially transforming precision cardio-oncology care. However, cost-benefit analysis, validation in diverse populations, and comparison with non-anthracycline CTR-CVT groups are needed.